Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intec Pharma

- PMLiVE

Merck & Co to buy IO specialists Immune Design for $300m

US giant looks to next generation technology

- PMLiVE

Greater Manchester backs move to outcome-based payment

Region teams up with Cancer Research UK to accelerate change

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

- PMLiVE

Xencor’s Novartis-partnered bispecific on hold after patient deaths

The two death’s included one case of CRS

- PMLiVE

Merck puts prostate cancer firmly in Keytruda’s sights

Lynparza combination could open up huge new market

- PMLiVE

Novartis’ Egatan gains US approval for neglected tropical disease

US approval removes barrier to greater access

- PMLiVE

Novartis first to benefit from NICE advice on ‘patient preference’

Consultancy spin-off looking to expand services

- PMLiVE

Analysts look beyond Keytruda in Merck’s future

CEO Frazier made to defend pipeline prospects

- PMLiVE

CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

Novartis agrees pricing deal with NHS England

- PMLiVE

Nerve centre gives Novartis edge in clinical trials

Algorithms predict potential delays

- PMLiVE

Novartis aims for 10 blockbuster launches by 2020

Includes new gene therapy Zolgensma

Novartis Gehry Building

Novartis forges AI alliance with Oxford University

Part of Novartis drive to become 'data-driven' pharma company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links